SCHEMBL2018800

SCHEMBL2018800

COc1ccc(CCc2cn3c(N)nnc3c(N)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.46
ALDH1A1 P00352 3/20 0.43
CYP2D6 P10635 1/20 0.43
ATM Q13315 1/20 0.43
ADORA1 P30542 5/20 0.40
ADORA2A P29274 4/20 0.40
TAAR1 Q96RJ0 1/20 0.40
ADORA3 P0DMS8 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAOB P27338 1/20 0.37
PDE8B O95263 1/20 0.37
CSF1R P07333 1/20 0.37
NTRK2 Q16620 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2026371 0.85 HPSE (0.43) DHFRALDH1A1ADORA1ADORA2ATSHR
SCHEMBL2025901 0.84 CYP19A1 (0.48) DHFRALDH1A1CYP2D6ATMADORA1
SCHEMBL2023558 0.83 DHFR (0.43) DHFRADORA1ADORA2ATAAR1ADORA3
SCHEMBL2021765 0.83 DHFR (0.43) DHFRADORA1ADORA2ATAAR1ADORA3
SCHEMBL2021909 0.76 ADORA2A (0.61) ALDH1A1ADORA1ADORA2AADORA3KDM4E
SCHEMBL834551 0.66 TAAR1 (0.73) TAAR1MAOB
SCHEMBL12476781 0.66 TP53 (0.50) CYP2D6ADORA2AADORA3MAPTTSHR
SCHEMBL8746062 0.65 CYP19A1 (0.74) ALDH1A1TAAR1MAOB
SCHEMBL2018334 0.64 ADORA2A (0.43) ALDH1A1ADORA1ADORA2AADORA3HPGD
SCHEMBL18010607 0.62 TAAR1 (0.47) DHFRTAAR1RAB9AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329705-B2 Substituted triazolo-pyrazine compounds ARQULE, INC. (US) 2012-12-11 US disclosed
US-20110160215-A1 Substituted Triazolo-Pyrazine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160215-A1 Substituted Triazolo-Pyrazine Compounds MKI67, TP53, THPO DHFR 49/4885ALDH1A1 1473/4885CYP2D6 1112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.